Caribou Biosciences, Inc.’s CRBU share price has surged by 5.65%, which has investors questioning if this is right time to ...

Obe-cel is under regulatory review in both the EU and the U.K., and the Company expects to receive notification of approval status from the Medicines and Healthcare products Regulatory Agency (MHRA) ...

The cell and gene therapy company is cutting 47 employees and its entire lupus program to focus resources on two CAR Ts. The ...

Systemic lupus erythematosus: Clinical and immunologic ... disease expression and outcome in acute onset lupus. Ann. Rheum. Dis. 67(4), 500-504 (2008). Alarcon GS, McGwin G Jr, Petri M, Reveille ...

AstraZeneca's Saphnelo has become the first new drug to be approved to treat the autoimmune disease systemic lupus erythematosus ... by a new indication in acute lupus nephritis.

You wake up, scroll through your phone, skip breakfast, sit for hours, grab some fast food on the go, work late, binge on a ...

In a new study, researchers evaluated the potential relationship between disordered eating attitudes and nutritional status ...

A new literature review explores the emerging application of CAR-T cell therapy in treating people with Systemic Lupus ...

Join Drs Maureen McMahon and Michael Garshick as they discuss cardiovascular disease in patients with systemic lupus erythematosus, focusing on hidden risk and challenging clinical scenarios.

Approximately 15% to 30% of patients have lupus nephritis at the time of SLE diagnosis, with more patients at risk of developing lupus nephritis over the course of their disease. An estimated 30% ...

Living in areas with lower COI levels was associated with more severe disease presentation and poorer disease control among patients with cSLE.